World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 20 July 2020
Main ID:  EUCTR2013-002777-22-GB
Date of registration: 07/10/2013
Prospective Registration: Yes
Primary sponsor: University of Leeds, Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine
Public title: Targeted Ultrasound in Rheumatoid Arthritis (TURA)
Scientific title: Targeted Ultrasound in Rheumatoid Arthritis (TURA) - TURA
Date of first enrolment: 14/11/2013
Target sample size: 310
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002777-22
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: Clinical arm blinded to US data, imaging arm guided by US data for therapy modifications
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries of recruitment
Denmark France Germany Hungary Italy Japan Spain United Kingdom
Contacts
Name: Project Management   
Address:  37-39, avenue Ledru-Rollin 75012 Paris France
Telephone: +336 73 18 54 87
Email: Isabelle.Brohan@Chiltern.com
Affiliation:  Theorem Clinical Research
Name: Project Management   
Address:  37-39, avenue Ledru-Rollin 75012 Paris France
Telephone: +336 73 18 54 87
Email: Isabelle.Brohan@Chiltern.com
Affiliation:  Theorem Clinical Research
Key inclusion & exclusion criteria
Inclusion criteria:
1. Patients fulfilling the ACR/EULAR classification criteria 2010 for RA

Patients must be:

2. Within the two years of starting on methotrexate AND

3. Within 5 years of diagnosis AND

4. a) In a stable clinical disease activity state (clinical remission/LDAS /other physician deemed state) for at least 8 successive weeks before screening visit (with no change in DMARD +/- steroid therapy)
b) On methotrexate (as monotherapy or combination +/- = prednisolone 5mg oral daily)
c) On an acceptable (maximal tolerated) methotrexate dose, which, in the clinicans opinion, would justify escalation to adalimumab if a flare in disease activity occurs, as detailed in the protocol.

5. Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (oral/parenteral /implantable hormonal contraceptives, intrauterine device or barrier and spermicide). Subjects must agree to use adequate contraception during the study and for at least 5 months after study completion (or longer if on relevant therapy and in line with local regulations). Male subjects must agree to ensure they or their female partner(s) use adequate contraception during the study and for at least 5 months after the end of the study period.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 264
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 46

Exclusion criteria:
1. Patients not on a stable dose of methotrexate within 8 weeks of screening, intolerance or contraindications (as per clinician judgment)

2. Intramuscular, intra-articular or change in oral corticosteroid within 8 weeks of screening visit.

3. Oral Prednisolone dose > 5 mg within 8 weeks of screening

4. Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening.

5. Patients who have previously received any biological therapy for RA.

6. History of severe allergic or anaphylactic reactions to human, humanised or murine monoclonal antibodies

7. Evidence of serious +/- uncontrolled concomitant disease which in the investigator’s judgment would deem the patient inappropriate for inclusion in the study: including (but not exclusively) cardiovascular (NYHA class III/IV heart failure), nervous system (demyelination), pulmonary (including obstructive pulmonary disease, pulmonary fibrosis), renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, ulcerative colitis, or Crohn’s disease.).

8. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds).

9. Any major episode of infection requiring hospitalisation or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening. Patients with persistent infections and patients at significant risk of infection (e.g. leg ulceration, indwelling urinary catheter, septic joint within 1 year (or ever if prosthetic joint still in situ).

10. Tuberculosis
a) Active tuberculosis (TB) requiring treatment within the previous 3 years. Patients previously treated for tuberculosis with no recurrence in 3 years are permitted.
b) Patients should be screened for latent TB (as per local guidelines) and, if positive, treated in line with local practice guidelines prior to commencing the study.

11. Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation.

12. Malignancy
Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including haematological malignancies and solid tumours, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 20 years unless related to primary disease under investigation.



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Body processes [G] - Immune system processes [G12]
Rheumatoid Arthritis
MedDRA version: 18.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Intervention(s)

Trade Name: Humira
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: ADALIMUMAB
CAS Number: 331731-18-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-

Primary Outcome(s)
Primary end point(s): Proportion of patients in whom there is a decrease in PD
Main Objective: To determine whether therapy modifications (including addition of Ultrasound-guided treatment change) can change power Doppler in patients with early Rheumatoid arthritis in a stable clinical disease activity state (clinical remission/LDAS/other physician deemed acceptable state).
Secondary Objective: In patients with early RA in a stable clinical state:
1. To evaluate change in Ultrasound (US) parameters over time
2. To determine whether addition of US-guided therapy modifications leads to:
• Reduced structural damage progression
• Better functional outcomes
3. To assess the impact of US on clinical management
4. To identify the predictive factors for achievement of:
• Sustained imaging/clinical remission
• Lack of structural damage progression
• Improvement in functional outcomes
5. Determine biological therapy (adalimumab) usage in each arm
6. To evaluate steroid need/exposure in each arm
7. To evaluate co-morbidity with the a treat to target and US and treat to target approach
8. To evaluate US-based parameters (those in the standard protocol or additional measures) to address questions related to pathology and response further.
Timepoint(s) of evaluation of this end point: W48 after randomisation
Secondary Outcome(s)
Timepoint(s) of evaluation of this end point: Change from baseline in:
1. Total PD score: W48
2. GS: W48
3. X-ray scores: W48, W96
4. HAQ-DI scores: W48, W96
5. Bone densitometry scores: W48, W96
6. RA-WIS score (if RA-WIS is available in participating country): W48, W96
7. EQ-5D score: W48, W96
8. Proportion of patients requiring biologic therapy: W48, W96
9. Total steroid exposure: W48, W96
10. Co-morbidity Evaluation
Secondary end point(s): Change from baseline in:
1. Total PD score
2. GS
3. X-ray scores
4. HAQ-DI scores
5. Bone densitometry scores
6. RA-WIS score (if RA-WIS is available in participating country)
7. EQ-5D score
8. Proportion of patients requiring biologic therapy
9. Total steroid exposure
10. Co-morbidity Evaluation
Secondary ID(s)
HG/1096
Source(s) of Monetary Support
AbbVie Ltd, Abbott House
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 14/11/2013
Contact:
Results
Results available: Yes
Date Posted: 01/07/2020
Date Completed: 30/07/2018
URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002777-22/results
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey